These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 26563355)
1. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355 [TBL] [Abstract][Full Text] [Related]
2. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021 [TBL] [Abstract][Full Text] [Related]
3. N of 2 Responders with LMNA-NTRK1. Lih CJ; Chen AP J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563357 [No Abstract] [Full Text] [Related]
4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971 [TBL] [Abstract][Full Text] [Related]
5. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697 [TBL] [Abstract][Full Text] [Related]
6. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414 [TBL] [Abstract][Full Text] [Related]
7. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764 [TBL] [Abstract][Full Text] [Related]
8. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704 [TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295 [TBL] [Abstract][Full Text] [Related]
10. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529 [TBL] [Abstract][Full Text] [Related]
11. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381 [TBL] [Abstract][Full Text] [Related]
12. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Amatu A; Somaschini A; Cerea G; Bosotti R; Valtorta E; Buonandi P; Marrapese G; Veronese S; Luo D; Hornby Z; Multani P; Murphy D; Shoemaker R; Lauricella C; Giannetta L; Maiolani M; Vanzulli A; Ardini E; Galvani A; Isacchi A; Sartore-Bianchi A; Siena S Br J Cancer; 2015 Dec; 113(12):1730-4. PubMed ID: 26633560 [TBL] [Abstract][Full Text] [Related]
13. Foretinib Overcomes Entrectinib Resistance Associated with the Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555 [No Abstract] [Full Text] [Related]
14. Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. Wong V; Pavlick D; Brennan T; Yelensky R; Crawford J; Ross JS; Miller VA; Malicki D; Stephens PJ; Ali SM; Ahn H J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563356 [No Abstract] [Full Text] [Related]
15. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model. Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194 [TBL] [Abstract][Full Text] [Related]
16. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers. Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889 [TBL] [Abstract][Full Text] [Related]
17. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792 [TBL] [Abstract][Full Text] [Related]
18. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605 [TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a novel Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424 [TBL] [Abstract][Full Text] [Related]
20. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]